Dental pulp histological respond to MTA, CEM and BIODENTI
Not Applicable
Recruiting
- Conditions
- Pulpitis.Pulpitis
- Registration Number
- IRCT2017091728804N2
- Lead Sponsor
- Vice Chancellor for research of Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
human premolars; no fillings; cervical erosion; caries; teeth that are going to be extracted for orthodontic treatment; both gender; 14 - 25 years of age. Exclusion criteria: previous caries; filling; history of trauma; periodontal disease; severe pain; need to early extraction; unwillingness to cooperate.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inflammation type. Timepoint: 6 weeks after intervention. Method of measurement: Measurement on pathology slide.;Formation of odontoblast cell. Timepoint: 6 weeks after intervention. Method of measurement: Measurement on pathology slide.;Width of dentin bridge. Timepoint: 6 weeks after intervention. Method of measurement: Measurement on pathology slide.;Forming dentin bridge. Timepoint: 6 weeks after intervention. Method of measurement: Measurement on pathology slide.;Necrosis. Timepoint: 6 weeks after intervention. Method of measurement: Measurement on pathology slide.;Severity of inflammation. Timepoint: 6 weeks after intervention. Method of measurement: Measurement on pathology slide.;Extent of inflammation. Timepoint: 6 weeks after intervention. Method of measurement: Measurement on pathology slide.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of MTA, CEM, and Biodentin in modulating dental pulp inflammation in Pulpitis?
How does the histological response of dental pulp to CEM compare with MTA and Biodentin in orthodontic patients with Pulpitis?
Are there specific biomarkers that correlate with favorable pulp healing outcomes following MTA, CEM, or Biodentin application in Pulpitis cases?
What are the potential adverse events associated with CEM, MTA, and Biodentin in dental pulp treatment, and how are they managed?
What is the current landscape of bioactive dental materials for Pulpitis treatment, and how do CEM, MTA, and Biodentin fit within this context?